Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
In a randomized trial comparing pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel, the pertuzumab combination resulted in a median overall survival of 56 months in women with metastatic HER2-positive breast cancer.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 19, 2015
|
| In: |
The New England journal of medicine
Year: 2015, Volume: 372, Issue: 8, Pages: 724-734 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1413513 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1056/NEJMoa1413513
|
| Author Notes: | Sandra M. Swain, M.D., José Baselga, M.D., Sung-Bae Kim, M.D., Jungsil Ro, M.D., Vladimir Semiglazov, M.D., Mario Campone, M.D., Eva Ciruelos, M.D., Jean-Marc Ferrero, M.D., Andreas Schneeweiss, M.D., Sarah Heeson, B.Sc., Emma Clark, M.Sc., Graham Ross, F.F.P.M., Mark C. Benyunes, M.D., and Javier Cortés, M.D., for the CLEOPATRA Study Group |
| Summary: | In a randomized trial comparing pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel, the pertuzumab combination resulted in a median overall survival of 56 months in women with metastatic HER2-positive breast cancer. |
|---|---|
| Item Description: | Gesehen am 19.07.2017 |
| Physical Description: | Online Resource |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1413513 |